Glaucoma can be regarded as a group of diseases that have as a common end-point a characteristic optic neuropathy. In glaucoma, eye pressure plays a role in damaging the delicate nerve fibers of the optic nerve...


Age related macular degeneration (AMD) is a severe and sight threatening condition and is the leading cause of vision loss in elderly people.
It occurs when the macular retina develops degenerative lesions causing the loss of the...


Two types of cancers can be found in the eye.
Primary intraocular cancers start inside the eyeball. In adults, melanoma is the most common primary intraocular cancer, followed by primary intraocular lymphoma...

VexO Pharmaceuticals is committed to discovering new breakthroughs in the treatment of eye disorders that can improve the lives of patients by repurposed existing drugs . Our ophthalmic research programs are focused on addressing the leading causes of blindness, including Glaucoma, atrophic age-related macular degeneration (AMD), neovascular AMD, ocular cancer and other retinal diseases that cause significant visual impairment and the possibility to lose sight permanently.

Coupling the Sentinel Pathway Reporter System developed at VexO with our expertise in ophthalmic disorders, our scientists are able to test activity of drugs directly and be at the forefront of scientific research in the fields of target. Believing in this system, we aim to develop therapeutics, expand our understanding of disease biology while identifing biomarkers that will allow one to detect and monitor a wide range of pathways that effect ocular diseases.

With numerous drugs available in the market, repurposing them for different applications gives an alternate perspective to therapy development. With repurposing, pre-clinical and clinical development will not only be safer as the side effects are already known, but also faster and hence more financially feasible.